Skip to main content

Table 1 Patient’s descriptive characteristics and extraocular symptoms

From: Conventional immunosuppressive therapy in severe Behcet’s Uveitis: the switch rate to the biological agents

(n = 76)

Mean ± sd (Min-Max)

Age (year)

31.46 ± 8.75 (18–58)

Follow-up time (month)

38.70 ± 25.62 (6–96)

 

n (%)

Gender

Male

51 (67.1)

Female

25 (32.9)

Uveitis type

Anterior

16 (21.1)

Posterior

12 (15.7)

Panuveitis

48 (63.2)

Laterality

Unilateral (right/left)

36 (20/16) (47.4, 26.3/21.1)

Bilateral

40 (52.6)

HLAB51

Positive

8 (10.5)

Negative

5 (6.6)

Not performed

63 (82.9)

Pathergy

Positive

9 (11.8)

Negative

18 (23.7)

Not performed

49 (64.5)

First line therapy

CS

11 (14.5)

CS + AZA

58 (76.3)

CS + CsA

1 (1.3)

CS + MTX

1 (1.3)

CS + AZA + CsA

4 (5.3)

IFNα2a

1 (1.3)

Extraocular symptoms

Recurrent oral ulcers

76 (100)

Genital ulceration

52 (68.4)

Folliculitis

47 (61.8)

Arthritis

41 (53.9)

Erythema Nodosum

19 (25.0)

CNS involvement

9 (11.8)

Thrombophlebitis

4 (5.2)

  1. AZA azathioprine, CS corticosteroid, CsA cyclosporine, IFNα2a interferon alpha2a